Effect of Sacubitril/Valsartan on Cardiac Function in Hypertensive Patients Stratified by BMI: A Real World Study
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18-70
SponsorBeijing Friendship Hospital
About this trial
The purpose of this study is to investigate the effect of sacubitril/valsartan on cardiac function assessed by cardiac magnetic resonance (CMR) in hypertensive patients stratified by BMI.
Eligibility criteria
Qualifiers
Patients with essential hypertension
18-70 years old
No major barriers to provide written consent
Disqualifiers
Secondary hypertension, except because of sleep apnea
cardiovascular disease (myocardial infarction, heart failure, stroke or coronary revascularization) within 6 months
Severe concomitant diseases (autoimmune disease, malignancy, late stage of liver diseases, respiratory diseases and digestive diseases)
Unable to understand or comply with the study procedures
Trial design
Treatments tested in this trial
- Sacubitril / Valsartan Oral Tablet [Entresto]
- ACEI/ARB
Treatment groups
180 Participants
are divided into 2 treatment groupsLocations
1Beijing Friendship Hospital, Capital Medical University100050, BeijingBeijing Municipality, China
Sponsors and collaborators
Beijing Friendship Hospital
Lead sponsor
Source ClinicalTrials.gov